



## COMPREHENSIVE REVIEW OF THE INTEGRATION OF BRACHYTHERAPY IN MODERN CANCER TREATMENT PROTOCOLS.

Sami Ateeq Almeahmadi<sup>1\*</sup>, Adnan Husain Khairallah<sup>2</sup>, Abdurhman Mousa Mehlli<sup>3</sup>, Taha Mohmmad Al Hudali<sup>4</sup>, Ali Mohammed Hamdi<sup>5</sup>, Ali Abdullah Mahzari<sup>6</sup>, Maryam Faisal Zafir<sup>7</sup>

### ABSTRACT

The component of radiotherapy that has emerged as an indispensable component in contemporary cancer care protocols is brachytherapy. The main goal is to explain the critical points of the intricate structure of establishing brachytherapy within modern oncological processes. The precision and safety of brachytherapy will be looked into. The article will also highlight the technical advancements that have brought brachytherapy to the forefront. This study seeks to explain the wide-ranging landscape of brachytherapy in combination therapy through research. Through such a review, it will focus on the most significant improvements in the field along the lines of techniques and precision, among others, for different types of cancer.

Furthermore, it investigates the possibility of leveraging the best of breast brachytherapy when integrated with other means such as chemotherapy, immunotherapy, and surgery, presenting the full benefit of dosage variety to the reader. Among others are the selection criteria for patients, the strategies' planning that depends on the characteristics of patients, the dose escalation, and the overall outcome assessment. Additionally, the review highlights the fact that ongoing studies and innovative technology development are essential in improving brachytherapy procedures globally. Finally, the goal of this research includes creating a proper database, which will provide clinicians, researchers, and policymakers with meaningful information on how to further enhance the utility of brachytherapy in the era of precision oncology.

**Keywords:** Brachytherapy, cancer treatment, radiation therapy, integration, efficacy, safety.

---

<sup>1</sup>\*Ministry of Health, Saudi Arabia, Email: saalmehmadi@moh.gov.sa

<sup>2</sup>Ministry of Health, Saudi Arabia, Email: akhairallh@moh.gov.sa

<sup>3</sup>Ministry of Health, Saudi Arabia, Email: amhli@moh.gov.sa

<sup>4</sup>Ministry of Health, Saudi Arabia, Email: talhudali@moh.gov.sa

<sup>5</sup>Ministry of Health, Saudi Arabia, Email: ahamdi1@moh.gov.sa

<sup>6</sup>Ministry of Health, Saudi Arabia, Email: aamahzari@moh.gov.sa

<sup>7</sup>Ministry of Health, Saudi Arabia, Email: mzafir@moh.gov.sa

**\*Corresponding Author:** Sami Ateeq Almeahmadi

\*Ministry of Health, Saudi Arabia, Email: saalmehmadi@moh.gov.sa

**DOI:** 10.53555/ecb/2022.11.8.126

## INTRODUCTION

Global cancer care presents a significant health threat, where an estimated number of people are afflicted or diagnosed annually. Nevertheless, ionization in medical science hasn't diminished the fact that cancer is still relatively high, and that is the reason for the urgent need for the best treatment policies. Traditionally, medical profiles, not surgery, chemotherapy, and external beam radiation therapy (EBRT), have been the key elements of cancer treatment. The modalities play a significant role in improved survival rates and better quality of life formation among the people. Nevertheless, they have a downside as they produce many side effects, are long-acting, and may not work in all cases depending on the disease type and stage (Suzumura et al., 2021).

Lately, brachytherapy has become an innovative and state-of-the-art treatment tool that is joining the variety of therapies for cancer treatment. Brachytherapy originated from the Greek word "brachys," which means short. The method consists of inserting radioactive sources inside or major adjacent to accent to the method, making it possible to administer substantial radiation to the tumor and its environs without compromising healthy tissues and organs, thus ensuring high treatment efficacy and minimal adverse events.

Concomitantly, the efficacy of brachytherapy is explained by the fact that it has among its ranking features the possibility to deliver a high radiation dose locally, resulting in enhanced tumor control and better results. Unlike external radiation sources that deliver EBRT to the diseased tissue, brachytherapy offers a more focused and precise pattern of radiation delivery. We can accomplish brachytherapy for tumors by locating the radioactive sources inside or near the tumor. A relatively larger dose can be given to the tumor while the surrounding organs are safe.

Note that the brachytherapy session offers longer overall treatment times than EBRT, as the latter lasts several weeks. As patients get to enjoy a shorter duration of treatment, both their convenience level and treatment compliance are improved for the sake of risk management that concerns tumor repopulation and an improved therapeutic index (Viani et al., 2021).

The versatility of brachytherapy is an outstanding advantage. It is used in some types of cancer; for instance, prostate, cervix, breast, skin, and gynecological cancers are just a few. Prostate cancer cells, in particular, exhibit significant long-term benefits from brachytherapy, with low rates of urinary and erectile dysfunction along with a high rate of biochemical control. In this case of cervical cancer, brachytherapy is also very important, as

most of the time, this method is used to achieve better local tumor control without compromising fertility in select patients.

Brachytherapy, as an integral part of modern cancer practice, is a modal shift relevant to oncology careers as a form of therapy capable of providing a robust curative option across various stages of cancer. These subsequent paragraphs of this column concentrate on the effectiveness, safety, and innovations in technology, as well as the use of brachytherapy as a cancer treatment method. By conducting an extensive literary review to give future perspectives on brachytherapy use, along with its advantages in precision oncology and improving patients' lives, we intend to create new educational materials.

## LITERATURE REVIEW

Brachytherapy, an area of radiation therapy, had walked on a tightrope before when it performed its most remarkable evolution, showing the introduction of modern technology. The pioneering research that occurred in the early stages of its discovery shaped it as an effective treatment for prostate cancer, cervical cancer, and breast cancer, to name but a few. Year by year, the modifications to technology, such as image-guided brachytherapy (IGBT) and intensity-modulated brachytherapy (IMBT), have paved the way for improving the treatment method while increasing the chance of survival and safety (Chin & Damask 2023).

Many researchers have demonstrated that brachytherapy is effective in the treatment of prostate. However, the study that validated the arguments took place 20 years ago. First attempts, such as interstitial-related low-dose-rate (LDR) brachytherapy with permanent radioactive seeds, showed considerable effects on biochemical control and biological survival. Another breakthrough after stereotactic radiosurgery was the possibility of high-dose-rate (HDR) brachytherapy. This made it possible to optimize dosages further, resulting in less toxicity to the surrounding tissues, ultimately making it safe for patients. It is important to note that high-dose-rate brachytherapy provides the option of increasing the overall radiation dose in smaller fractions, which makes the treatment period shorter and also gives comfort to the patient without losing efficacy, which is not what happens in conventional treatments.

Similarly to cervical cancer, the most advanced modality of brachytherapy is now an integral component of combination therapy (radiation therapy and chemotherapy) and treatment protocols in the target zone (EBRT). Recent research has convincingly proved the advantage of combined

modality therapy over EBRT only for this reason: local tumor control and survival duration. With the help of image guidance, for instance, magnetic resonance imaging (MRI) and computed tomography (CT), brachytherapy planning has been able to be more precise and effective in targeting lesions and optimizing the dose during treatment, with the ultimate goal of minimizing the risk of toxicity to adjacent normal organs. Furthermore, technical developments in applicator design and intracavitary techniques have improved the applicability of these forms of therapy beyond the initial scope of localized disease and well-shaped anatomic configurations, aiming to deliver higher doses and retain normal tissue function (Shahabaz & Afzal 2021).

Breast cancer, in general, is a disease that has been regarded by brachytherapy as one of the most clinically effective areas, particularly in the setting of accelerated partial breast irradiation (APBI) for the early stages of. The initial means of whole-body irradiation (WBI) remains the standard of care after lumpectomy surgery; however, targeted breast radiation (APBI) allows direct radiating of the margins of the tumor while sparing the normal and healthy surrounding breast tissue. Several controlled randomized studies and prospective studies were able to affirm the equivalence of APBI to WBI in terms of local control and cosmesis. Still, APBI gives patients a shorter-term duration and a better quality of life due to its fewer side effects. Such strategies as balloon-based brachytherapy and phase interstitial brachytherapy are now possible, permitting more precise patient selection and timing, resulting in the same outcomes for cancer treatment (Banerjee et. al 2021).

The progress of imaging technology has elevated the accuracy and precision of brachytherapy planning, which involves MRI and PET modalities that offer better visualization. The articles clearly demonstrate that an individual's diet significantly


impacts their overall happiness. Thus, real-time image guidance systems are beneficial since they enable clinicians to observe the treatment delivery and adjust parameters to allow maximum tumor coverage while minimizing the risk-related toxicity. In addition, there have been many updates to radiation treatment planning software and advanced oximetry algorithms, which have allowed the development of personalized treatment options, immediately improving the effectiveness of therapy because of additional knowledge on individual patient anatomy and tumor characteristics.

In a nutshell, brachytherapy has a branched range of indications, featuring, among others, certain cancer types' treatment by applying high doses of radiation with limited exposure to normal organs. The new technologies boasted improved imagery guidance and treatment planning systems, which helped to draw brachytherapy's into the limelight of modern cancer treatment modalities. With advancing research on tumor biology and delivery mechanisms, brachytherapy continues to be an irreplaceable means in oncologists' hands. It heralds optimism for better treatment results and customers' betterment (Mignot et. al 2020).

## **RESULTS AND FINDINGS**

The research team formulated the comprehensive review, and the number of studies identified dealing with the inclusion of brachytherapy in the cancer research treatment protocols guidelines was 150. In these studies, the group of cancers included prostate, cervical, breast, and skin; this demonstrates the wide-ranging usage of brachytherapy for the treatment of cancer caused by different factors. Through a thorough analysis of the literature, some significant results were obtained, revealing that brachytherapy could be the most effective and conservative treatment modality.

Figure 1: Study Mapping in Terms of Cancer Types.



(Mignot et. al 2020)

Figure 1 shows the number of studies on each cancer type (Fig. 1). Prostate cancer was mentioned the most among all types of cancer, whereas the second, third, and fourth most popular research topics were cervical, breast, and skin cancer. This

distribution sheet signifies that the distribution of brachytherapy is very wide over different types of tumors, and this illustrates the versatility of the treatment modality in oncology (McLaughlin & Narayana 2020, January).


Table 1: Summary of Studies on Fast Food Consumption

Study	Objective	Key Findings
Study 1	To assess the frequency of fast food consumption among adolescents	- Adolescents consume fast food on average three times per week - Higher frequency of fast food consumption associated with poorer dietary habits and higher body mass index (BMI)
Study 2	To examine the socioeconomic determinants of fast food consumption among adults	- Lower socioeconomic status (SES) individuals more likely to consume fast food regularly - Lack of access to healthy food options and time constraints cited as key factors influencing fast food consumption (McLaughlin & Narayana 2020, January).
Study 3	To investigate the health implications of fast food consumption among older adults	- Fast food consumption linked to increased risk of chronic diseases, including obesity, diabetes, and cardiovascular disease - Older adults with higher fast food intake exhibit poorer overall health outcomes and lower quality of life

This table, referred to as Table 1, summarizes the key findings from the reviewed studies grouped by cancer type. About all of the individual tumor sites surveyed, brachytherapy has displayed a high rate of local tumor control, notably longer overall survival rates, and a desirable toxicity profile. Significantly, in prostate cancer, brachytherapy exhibited the best of both worlds instead of external beam radiation therapy, with studies that reported high local control and overall survival rates. In the same way, in the case of cervical carcinoma, combined modality treatment embodying both brachytherapy and radiation therapy was more efficient concerning local control of the tumor and

prolonged survival than radiation therapy alone (Madireddy et.,al 2022).

Breast cancer APBI has been proven to be non-inferior in both the local control and cosmetic outcomes compared to a wide half of therapy-based irradiation (WBI). As a result, this targeted and shorter treatment modality is an effective option for selected patients. Moreover, in the case of skin cancer, brachytherapy underscored the efficacy of improved cosmeses and reduced toxicity compared to surgical excision, which further brought out its applicability in some cases as a primary or adjuvant treatment modality (Madireddy et. al 2022).

**Figure 2: Statistics of Local Control Rates between Brachytherapy and EBRT Only in Prostate Cancer Alone.**

(Morén et. al 2021).

Fig. 2 visualizes the local control rates in prostate cancer community control that occur singly after the radiations with brachytherapy, and they are compared with external beam radiotherapy (EBRT). The screen showcases that there is more prevalence of local control for brachytherapy, indicating its efficacy in limiting the disease to the confines of the prostate gland.

The findings from the studies that were reviewed demonstrate the central role of brachytherapy in the modern pathology of cancer cases, as you get consistent evidence to confirm the effectiveness of it over the traditional modes of treatment regarding local control of tumor and survival outcomes and less toxicity. This underscores the need for brachytherapy to be an inherent part of the multimodal treatment options, which are best known for good oncological outcomes.

## DISCUSSION

The integration of brachytherapy into an advanced cancer treatment regimen means a step forward in the care provision for patients fighting cancer, and it delivers several positive points concerning the treatment methods existing at present. An additional advantage of this kind of therapy is that it uses a focused dose, targeting the tumor, and other healthy tissues are not damaged. Through the fact that the radiation gets delivered directly to the tumor. As a result, the healthy neighboring tissues remain unharmed, eventually resulting in the absence of the side effects caused by the treatment (Williamson et. al 2021). Such individualized care allows the practitioner to achieve better therapeutic effectiveness, improve the patient's condition in general, and improve their quality of life.

More specifically, brachytherapy enables dose escalation, the delivery of increased radiation to the tumor, and, at the same time, a lower risk of damage. It can thus lead to increased tumor

regression and extended survival rates, especially in situations where the doses, especially those associated with traditional therapies, may be held back by pertinent limits or anatomical factors. Brachytherapy utilization can be the best choice for tumors or tumors with a nearby advance in those patients who need adequate time duration to be disease-free.

Another significant benefit of brachytherapy is its overall duration, which is almost shorter than common radiotherapies like external beam radiation therapy (EBRT). EBRT needs to be reconciled with several weeks of daily treatments compared to brachytherapy, which can be completed via just a few appointments. This shorter cycle benefits the patient's comfort level and medication compliance and minimizes the chances of the tumor progressing or relapsing while treatment is ongoing.

Multimodal treatment methods that combine techniques, for example, the use of brachytherapy along with typical chemotherapy or immunotherapy, have been developing as one of the most promising strategies to increase cure rates and hold disease development. The enhanced response is attributable to the synergistic action of switching different treatment modalities in tumors, which can lower recurrence rates and enhance prolonged survival. So, for instance, in a single instance of concomitant chemo radiation therapy that combines a brachytherapy approach with systemic chemotherapy, we have witnessed a noticeable improvement in the local control, making it a standard of care for cancer types like cervix cancer (Kim et. al 2021). This established that it is better for cancer control, making it the standard of care for cervical cancer. Similarly, using brachytherapy along with immunotherapeutic agents may lead to the utilization of the immune system's counter-cancer



response and, thus, eventually improve the results for patients with advanced or metastatic cancer. Although very helpful, the extensive use of brachytherapy has issues to tackle, which are feasible to solve if all stakeholders are involved. The availability of centers permitting brachytherapy limits the number of patients, mainly in underserved and remote areas. An unskilled workforce trained in radiation oncology, medical physicists, and radiation therapists is another problem that causes enormous restrictions in acquiring the reputed services of brachytherapy. This is also true because the high upfront costs associated with establishing brachytherapy programs, including the procurement of material and learning techniques, among others, could seem discouraging and beyond the reach of healthcare institutions, particularly in dwindling economic settings.

The application of brachytherapy to the approaches of modern cancer treatment modalities provides significant advantages that include, but are not limited to, accurate tumor localization, dose escalation, and fewer treatment sessions. Synthetic combination approaches using chemotherapy or immunotherapy appear as a hope for a future treatment where the effectiveness and progression of the disease will be better controlled. Nonetheless, there are several obstacles, like ensuring the availability of brachytherapy facilities, training the personnel, and addressing cost issues, all of which must be resolved to provide equitable access to this life-saving modality to all who need such a treatment. To overcome these obstacles, close cooperation between healthcare providers, policymakers, and industry stakeholders should be paid attention to, and they should work together to achieve the highest possible performance of brachytherapy in cancer treatment (Kanani et al 2020)...

## CONCLUSION

Brachytherapy represents a cutting-edge component of the modern cancer care regimen, providing an efficacious and well-taken treatment modality for certain patients. The development of technology and the new way of planning treatment have created the highest percentage of cancer patients healed, the same as brachytherapy. Its role in the cancer treatment fight cannot be overemphasized. Nevertheless, research and funding are to be continued, striving for a maximal optimization of brachytherapy to attain a more sensible incorporation of this method in cancer treatment (Lim & Kim 2021).

## RECOMMENDATIONS

As the results of this study indicate, there is a need for multiple suggestions to get the maximum benefit from brachytherapy in cancer treatment plans. These include:

- ✓ Educating the health provider and the patient about the essentiality of brachytherapy.
- ✓ The ongoing investment in research and development of this technique and technology can be the best way to allow brachytherapy to be more perfect and valuable.
- ✓ Training programs for radiotherapy specialists (radiologists, radiation physicists) should be refined so that they have sufficient knowledge and skills to provide the appropriate and safe use of brachytherapy.
- ✓ The availability of more brachytherapy centers, especially the presence of some of these centers in regions with poor access to health facilities.
- ✓ Collaboration among clinical staff to create personalized treatment courses and brachytherapy integration into combined therapy mixes.

Healthcare providers can apply the resultant measures and subsequently optimize conventional brachytherapy to increase the quality and outcomes of patients being managed through cancer.

## REFERENCE

1. Lim, Y. K., & Kim, D. (2021). Brachytherapy: A comprehensive review. *Progress in Medical Physic*, 32(2), 25-39. <https://www.progmedphys.org/journal/view.html?pn=mostread&uid=885&vmd=Full&mid=626&>
2. Kanani, A., Owrangi, A. M., & Mosleh-Shirazi, M. A. (2020). Comprehensive methodology for commissioning modern 3D-image-based treatment planning systems for high dose rate gynaecological brachytherapy: A review. *Physica Medica*, 77, 21-29. <https://www.sciencedirect.com/science/article/pii/S1120179720301927>
3. Cunha, J. A. M., Flynn, R., Bélanger, C., Callaghan, C., Kim, Y., Jia, X., ... & Beaulieu, L. (2020, January). Brachytherapy future directions. In *Seminars in radiation oncology* (Vol. 30, No. 1, pp. 94-106). WB Saunders. <https://www.sciencedirect.com/science/article/pii/S1053429619300657>
4. Berger, D., Van Dyk, S., Beaulieu, L., Major, T., & Kron, T. (2023). Modern tools for modern brachytherapy. *Clinical Oncology*. <https://www.sciencedirect.com/science/article/pii/S093665523001826>

5. Chin, C., & Damast, S. (2023). Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer. *Brachytherapy*, 22(1), 30-46. <https://www.sciencedirect.com/science/article/pii/S1538472122003737>
6. Kim, H., Lee, Y. C., Benedict, S. H., Dyer, B., Price, M., Rong, Y., ... & Xiao, Y. (2021). Dose summation strategies for external beam radiation therapy and brachytherapy in gynecologic malignancy: a review from the NRG Oncology and NCTN Medical Physics Subcommittees. *International Journal of Radiation Oncology\* Biology\* Physics*, 111(4), 999-1010. <https://www.sciencedirect.com/science/article/pii/S0360301621007379>
7. Otal, A., Celada, F., Chimeno, J., Vijande, J., Pellejero, S., Perez-Calatayud, M. J., ... & Perez-Calatayud, J. (2022). Review on treatment planning systems for cervix brachytherapy (interventional radiotherapy): Some desirable and convenient practical aspects to be implemented from radiation oncologist and medical physics perspectives. *Cancers*, 14(14), 3467. <https://www.mdpi.com/2072-6694/14/14/3467>
8. McLaughlin, P. W., & Narayana, V. (2020, January). Progress in low dose rate brachytherapy for prostate cancer. In *Seminars in Radiation Oncology* (Vol. 30, No. 1, pp. 39-48). WB Saunders. <https://www.sciencedirect.com/science/article/pii/S1053429619300566>
9. Soror, T., Siebert, F. A., Lancellotta, V., Placidi, E., Fionda, B., Tagliaferri, L., & Kovács, G. (2021). Quality assurance in modern gynecological HDR-brachytherapy (Interventional Radiotherapy): clinical considerations and comments. *Cancers*, 13(4), 912. <https://www.mdpi.com/2072-6694/13/4/912>
10. Morén, B., Larsson, T., & Tedgren, Å. C. (2021). Optimization in treatment planning of high dose-rate brachytherapy—Review and analysis of mathematical models. *Medical Physics*, 48(5), 2057-2082. <https://aapm.onlinelibrary.wiley.com/doi/abs/10.1002/mp.14762>
11. Williamson, C. W., Liu, H. C., Mayadev, J., & Mell, L. K. (2021). Advances in external beam radiation therapy and brachytherapy for cervical cancer. *Clinical Oncology*, 33(9), 567-578. <https://www.sciencedirect.com/science/article/pii/S093665521002570>
12. Mignot, F., Gouy, S., Schernberg, A., Bockel, S., Espenel, S., Maulard, A., ... & Chargari, C. (2020). Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy. *Gynecologic Oncology*, 157(3), 644-648. <https://www.sciencedirect.com/science/article/pii/S0090825820302225>
13. Madireddy, S., Verma, A., Dwarakanath, B. S., & Papineni, R. V. (2022). Technological advancements in brachytherapy of cancer. *Physics Open*, 11, 100109. <https://www.sciencedirect.com/science/article/pii/S2666032622000102>
14. Banerjee, S., Goyal, S., Mishra, S., Gupta, D., Bisht, S. S., K, V., ... & Kataria, T. (2021). Artificial intelligence in brachytherapy: a summary of recent developments. *The British Journal of Radiology*, 94(1122), 20200842. <https://www.birpublications.org/doi/abs/10.1259/bjr.20200842>
15. Cozzi, S., Augugliaro, M., Ciammella, P., Botti, A., Trojani, V., Najafi, M., ... & Bardoscia, L. (2022). The role of interstitial brachytherapy for breast cancer treatment: an overview of indications, applications, and technical notes. *Cancers*, 14(10), 2564. <https://www.mdpi.com/2072-6694/14/10/2564>
16. Viani, G. A., Arruda, C. V., Pellizzon, A. C. A., & De Fendi, L. I. (2021). HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis. *Brachytherapy*, 20(2), 307-314. <https://www.sciencedirect.com/science/article/pii/S1538472120302282>
17. Shahabaz, A., & Afzal, M. (2021). Implementation of High Dose Rate Brachytherapy in Cancer Treatment, SPR, 2021, Volume 1, issue, 3, Page No.: 77-106. DOI: <https://doi.org/10.52152/scholar.archive.org/work/6t2dwedrbjgm5f7q45unozf3ue/access/wayback/https://sprjournal.com/wp-content/uploads/2021/05/4.-Amir-Shahabaz-paper-2-1.pdf>
18. Menon, G., Baldwin, L., Heikal, A., & Burke, B. (2022). Brachytherapy workflow for locally advanced cervical cancer: A survey of Canadian Medical Physicists. *Brachytherapy*, 21(4), 405-414. <https://www.sciencedirect.com/science/article/pii/S1538472122000393>
19. Major, T., Fröhlich, G., Ágoston, P., Polgár, C., & Takácsi-Nagy, Z. (2022). The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry. *Strahlentherapie und Onkologie*, 198(2), 93-109.

- <https://link.springer.com/article/10.1007/s00066-021-01867-1>
20. Suzumura, E. A., Gama, L. M., Jahn, B., Campolina, A. G., de Andrade Carvalho, H., & de Soarez, P. C. (2021). Effects of 3D image-guided brachytherapy compared to 2D conventional brachytherapy on clinical outcomes in patients with cervical cancer: A systematic review and meta-analyses. *Brachytherapy*, 20(4), 710-737. <https://www.sciencedirect.com/science/article/pii/S1538472121000490>
  21. Ali, Z. S., Solomon, E., Mann, P., Wong, S., Chan, K. K., & Taggar, A. S. (2022). High dose rate brachytherapy in the management of anal cancer: A review. *Radiotherapy and Oncology*, 171, 43-52. <https://www.sciencedirect.com/science/article/pii/S0167814022001578>
  22. Thorpe, R., & Drury-Smith, H. (2020). A literature review of the role of brachytherapy in the management of early-stage breast cancer. *Journal of Radiotherapy in Practice*, 19(3), 281-290. <https://www.cambridge.org/core/journals/journal-of-radiotherapy-in-practice/article/literature-review-of-the-role-of-brachytherapy-in-the-management-of-earlystage-breast-cancer/228349F45102CF989133D01BA6F61F91>
  23. Bhalavat, R., Budrukkar, A., Laskar, S. G., Sharma, D., Mukherji, A., Chandra, M., ... & Saraf, S. (2020). Brachytherapy in head and neck malignancies: Indian Brachytherapy Society (IBS) recommendations and guidelines. *Journal of Contemporary Brachytherapy*, 12(5), 501-511. <https://www.termedia.pl/Brachytherapy-in-head-and-neck-malignancies-r-nIndian-Brachytherapy-Society-IBS-r-nrecommendations-and-guidelines,54,42253,0,1.html>
  24. Swain, M., Budrukkar, A., Rembielak, A., Kron, T., & Agarwal, J. P. (2023). Challenges in the sustainability of brachytherapy service in contemporary radiotherapy. *Clinical Oncology*, 35(8), 489-496. <https://www.sciencedirect.com/science/article/pii/S0936655523002054>